Therapeutic combinations comprising anti-CD73 antibodies and uses thereof
AssigneeMedImmune, LLC
InventorsKris Sachsenmeier, Erin Sult, Carl Hay, Edmund Poon
Life of this patent
Estimating the term…
Abstract
The present invention provides therapeutic combinations featuring anti-CD73 antibodies (e.g., MEDI9447) and A2A receptor inhibitors and methods of using such combinations for reducing tumor-mediated immunosuppression.
Claims15
A method of inhibiting tumor growth in a subject comprising administering an anti-CD73 antibody, wherein the anti-CD73 antibody is MEDI9447 or an antigen-binding fragment thereof, and an adenosine receptor inhibitor (A2Ari) for inhibiting tumor growth to the subject.
A method of increasing an anti-tumor immune response comprising administering an anti-CD73 antibody, wherein the anti-CD73 antibody is MEDI9447 or an antigen-binding fragment thereof, and an adenosine receptor inhibitor (A2Ari) to a subject in need thereof.
A method of treating a tumor in a subject comprising administering to the subject an anti-CD73 antibody, wherein the anti-CD73 antibody is MEDI9447 or an antigen-binding fragment thereof, and an adenosine receptor inhibitor (A2Ari).
Dependencies are inferred from the claim text.